DBV Technologies Says Pivotal Trial Met Primary Endpoint: Lower Bound Of The 95% Confidence Interval Of The Difference Between Treatment Arms Was 22.4%, Exceeding The Prespecified Threshold Of 15%

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!